Alphaeon to market Amaris excimer laser system in US

Alphaeon announced that it acquired a U.S. license from Schwind eye-tech solutions to market the Amaris excimer laser system, according to a press release. Alphaeon, a wholly owned subsidiary of Strathspey Crown Holdings, will oversee the U.S. Food and Drug Administration clinical trial required to market the product in the United States. The amount of the license was not disclosed.

Full Story →